Beijing Hotgen Biotech Hits Day Low of CNY 83.38 Amid Price Pressure

Beijing Hotgen Biotech Co., Ltd. experienced a significant decline in its stock price today, dropping by 6.27% and reaching an intraday low of CNY 83.38. This performance stands in stark contrast to the China Shanghai Composite, which gained 0.87% on the same day. Over the past week, the stock has fallen by 11.41%, and its one-month performance shows a notable decrease of 26.51%. Year-to-date, Beijing Hotgen's stock has plummeted by 47.84%, reflecting a challenging financial landscape for the company. The firm has reported negative results for the last 12 consecutive quarters, with a recent net profit of CNY -75.78 million, marking a decline of 58.81%. Additionally, the company's return on capital employed (ROCE) stands at a low -8.38%, indicating ongoing financial difficulties. Despite a three-year performance that shows a return of 91.13%, the stock's long-term growth prospects appear limited, with net sales declining by 4.41%. As a mid-cap player in the pharmaceuticals and biotechnology sector, Beijing Hotgen continues to face significant challenges in maintaining its market position.